Clik here to view.
Acucela to Present at ARVO 2016 Annual Meeting’s Education Courses in Seattle
SEATTLE Acucela Inc. (Tokyo: 4589) (“Acucela”), a clinical-stage ophthalmology company that specializes in identifying and developing novel therapeutics to treat and slow the progression of...
View ArticleClik here to view.
フランスの大学病院の1つがSpHb®、PVI®、SET®パルスオキシメトリーを搭載したマシモのRadical-7®を採用
スイス・ヌーシャテル （ビジネスワイヤ） — マシモ（NASDAQ:...
View ArticleClik here to view.
PerkinElmer and Genome Institute of Singapore Open Joint Research Laboratory...
WALTHAM, Mass. & SINGAPORE PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, and the Genome Institute of Singapore (GIS), a biomedical...
View ArticleClik here to view.
PPD Expands Medical Communications Operations into Asia-Pacific Region
WILMINGTON, N.C. Pharmaceutical Product Development, LLC (PPD) has expanded its medical communications services into the Asia-Pacific region, enabling the contract research organization (CRO) to...
View ArticleClik here to view.
含NMN的补品是一种全球首创的补品，添加了可能使人重返年轻态的物质NMN，在日本Amazon荣获“畅销商品”、“新商品排行榜”及“人气礼品排行榜”三项桂冠...
东京 (美国商业资讯)–新兴和制药株式会社（总公司位于东京都）从2015年4月1日起开始以抗衰老专用补品品牌“MIRAI LABORATORY”销售全球首创的添加β烟酰胺单核苷酸的补品“NMN＋Resveratrol”，本品在日本大型电子商务网站获得了“畅销商品”、“新商品排行榜”及“人气礼品排行榜”三项桂冠。该商品已在日本国内获得广泛好评，如今又在中国闪亮登场。 Rakuten Global...
View ArticleClik here to view.
革命性的人工晶状体– InFo Instant Focus© – 具备更大屈光度范围的型号现已上市
瑞士纳沙泰尔 — (美国商业资讯) — Swiss Advanced Vision公司(SAV-IOL SA – www.sav-iol.com)宣布，具备更宽屈光度范围的人工晶状体(IOL) InFo Instant Focus©现已上市，该型号适用于晶状体摘除后的白内障治疗。 Smart News Releases（智能新闻稿）是一个多媒体平台。在此处查看完整新闻稿：...
View ArticleClik here to view.
革命的眼内レンズのInFo Instant Focus©をより広範な度数範囲で提供
スイス・ヌーシャテル （ビジネスワイヤ） — Swiss Advanced Vision (SAV-IOL SA – www.sav-iol.com)は、水晶体摘出後の白内障治療が適応の眼内レンズ（IOL）であるInFo Instant Focus©をより広範な度数範囲で提供できるようになったと発表しました。 このSmart News...
View ArticleClik here to view.
Ora®がデビッド・ホランダー医師（M.D.、M.B.A.）を最高医学責任者（CMO）に任命
ボストン （ビジネスワイヤ） — 眼科用医薬品・医療機器の開発における世界一流パートナーのOra,...
View ArticleClik here to view.
Ora®任命David Hollander, M.D., M.B.A.为首席医学官
波士顿 (美国商业资讯) — 世界领先的眼科药品及器械开发伙伴Ora, Inc.今天宣布任命David A. Hollander, M.D., M.B.A.为首席医学官兼高级副总裁。Hollander博士的最近职务是Allergan®的治疗领域负责人兼临床开发副总裁，负责前段眼科和消费者眼护理的全球战略和临床开发项目。 Ora总裁兼首席执行官Stuart B....
View ArticleClik here to view.
Rhinoplasty, the Most Affected by Your Facial Impression, If the First...
SEOUL, South Korea Many people decide to have rhinoplasty expecting a beautiful nose. How pleasurable it will be if every patient could get the result that they have expected before surgery....
View ArticleClik here to view.
A Facial Bone Contouring Surgery of Korean Plastic Surgery Which Makes You...
SEOUL, South Korea Unlike in the past when the standard of beauty hugely relied on eyes and nose, facial contouring has become a key factor to determining a beautiful face. This Smart News Release...
View ArticleClik here to view.
Clik here to view.
Exelixis Announces First Quarter 2016 Financial Results and Provides...
SOUTH SAN FRANCISCO Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2016 and provided an update on progress toward delivering upon its key 2016 corporate...
View ArticleClik here to view.
サルタリス・メディカル・デバイシズによる滲出型AMD脈絡膜厚測定研究の結果がARVO 2016で発表される
シアトル （ビジネスワイヤ） — サルタリス・メディカル・デバイシズ・インク (SalutarisMD®)による滲出型加齢黄斑変性（滲出型AMD）脈絡膜厚測定研究 (DOCS)の結果が本日、視覚・眼科学研究協会（ARVO）年次総会における2件の発表で取り上げられました。 1件目のポスター発表はDr. Kamaljit...
View ArticleClik here to view.
Acucela Initiates Phase 2 Clinical Trial Addressing Proliferative Diabetic...
SEATTLE Acucela Inc. (Tokyo: 4589) (“Acucela”), a clinical-stage ophthalmology company that specializes in identifying and developing novel therapeutics to treat and slow the progression of...
View ArticleClik here to view.
Hoya Reports Fourth Quarter Results; Achieves Record Annual Sales and Profit
TOKYO HOYA Corporation (TOKYO:7741) today announced financial results for the fourth quarter and full-year ended March 31, 2016. During the quarter, revenues decreased by 4.5% to 121,666 million yen...
View ArticleClik here to view.
Collaborative Study of Whole Exome Sequencing Offers New Hope for Children...
SAN DIEGO Illumina, Inc. (NASDAQ: ILMN), Children’s National Health System and The University of Queensland (UQ) announced today that a study using whole exome sequencing (WES), a method to look at...
View ArticleClik here to view.
Illumina Registers MiSeqDx System in South Korea
SAN DIEGO Illumina, Inc. (NASDAQ: ILMN) today announced it has received a product approval certificate for the MiSeqDx® Instrument and the MiSeqDx Universal Kit with the Ministry of Food and Drug...
View ArticleClik here to view.
Cell Therapy Ltd. Grants Japan License To Daiichi Sankyo For Its Heart...
CARDIFF, Wales Cell Therapy Ltd. (CTL) today announced the granting of the Japan license for its innovative cardiac regeneration medicine, Heartcel™ (immuno-modulatory progenitor [iMP] cells) to...
View ArticleClik here to view.
Takeda Reports Results for Fiscal Year 2015 (April 2015 – March 2016) and...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502): FY2015: A year of turnaround to sustained growth; achieved full year management guidance • Underlying revenue up +3.4%...
View Article